Literature DB >> 18346039

Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome.

María C Fernández1, David Bes, María De Dávila, Susana López, Carlos Cambaceres, Marcelo Dip, Oscar Imventarza.   

Abstract

UNLABELLED: Post-Transplant Lymphoproliferative Disorder (PTLD) is a life threatening complication in organ transplant recipients. Risk factors include primary Epstein-Barr virus infection, intensity of immunosupression and cytomegalovirus infection.
OBJECTIVES: To evaluate the incidence, clinical presentation, risk factors, histopathologic appearance and outcome of pediatric liver recipients with PTLD at our institution.
METHOD: Retrospective, descriptive and observational analysis. Between November 1992 and December 2005, 383 liver transplants were performed. The diagnosis of PTLD was based on clinical history and physical examination and confirmed by histologic appearance and immunohistologic staining. Knowles' classification was used for histopathologic diagnosis.
RESULTS: The incidence of PTLD was 5.7% (n: 22p). The average onset after tansplantation (OLT) was 24.9 months. Clinical manifestations were malaise, anorexia, fever of more than 3 days, peripheral adenopathy, tonsillar hypertrophy, abdominal mass, hepatosplenomegaly, snoring, interstitial pulmonary infiltrate, G.T.-tract bleeding, rash, submaxilar mass. Histopathologic diagnosis were Plasmocytic Hyperplasia (n: 10), Polymorphic Lymphoproliferative Disorder (n: 8), Non-Hodgkin Lymphoma (n: 4). Mortality was 18%.
CONCLUSION: The clinical presentations were protean and not specific. A high index of suspicion is important for early diagnosis as it correlates with more benign lesions and more favorable outcume. The lower mortality rate in our series is concordant with that reported in more recent articles.

Entities:  

Mesh:

Year:  2008        PMID: 18346039     DOI: 10.1111/j.1399-3046.2008.00914.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

Review 1.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 2.  Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.

Authors:  Pavan Kedar Mukthinuthalapati; Raghavender Gotur; Marwan Ghabril
Journal:  World J Hepatol       Date:  2016-04-28

3.  Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.

Authors:  Ahad Eshraghian; Mohammad Hadi Imanieh; Seyed Mohsen Dehghani; Saman Nikeghbalian; Alireza Shamsaeefar; Frouzan Barshans; Kourosh Kazemi; Bita Geramizadeh; Seyed Ali Malek-Hosseini
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

4.  Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center.

Authors:  Hyung Joo Jeong; Yo Han Ahn; Eujin Park; Youngrok Choi; Nam-Joon Yi; Jae Sung Ko; Sang Il Min; Jong Won Ha; Il-Soo Ha; Hae Il Cheong; Hee Gyung Kang
Journal:  Korean J Pediatr       Date:  2017-03-27

5.  Role of Tacrolimus C/D Ratio in the First Year After Pediatric Liver Transplantation.

Authors:  Benas Prusinskas; Sinja Ohlsson; Simone Kathemann; Denisa Pilic; Kristina Kampmann; Rainer Büscher; Andreas Paul; Lars Pape; Peter F Hoyer; Elke Lainka
Journal:  Front Pediatr       Date:  2021-06-02       Impact factor: 3.418

6.  Treatment of recurrent posttransplant lymphoproliferative disorder of the central nervous system with high-dose methotrexate.

Authors:  Clare J Twist; Ricardo O Castillo
Journal:  Case Rep Transplant       Date:  2013-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.